Results 1 to 10 of about 24,351,477 (245)
Glucagon-like peptide 1 (GLP-1)
Molecular Metabolism, 2019 Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying ...
Peter Flatt +2 more
exaly +4 more sources
Lancet Diabetes and Endocrinology,the, 2021 BACKGROUND GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain.
Naveed Sattar +2 more
exaly +2 more sources
Lancet Diabetes and Endocrinology,the, 2019 BACKGROUND Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes ...
Søren Lund Kristensen +2 more
exaly +2 more sources
Circulation, 2022 Patients with type 2 diabetes are at high risk for development of cardiovascular disease, including myocardial infarction, stroke, heart failure, and cardiovascular death.
Darren K Mcguire +2 more
exaly +2 more sources
Central and peripheral GLP-1 systems independently suppress eating
Nature Metabolism, 2021 The anorexigenic peptide glucagon-like peptide-1 (GLP-1) is secreted from gut enteroendocrine cells and brain preproglucagon (PPG) neurons, which, respectively, define the peripheral and central GLP-1 systems. PPG neurons in the nucleus tractus solitarii
Daniel I Brierley +2 more
exaly +2 more sources
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Annual Review of Medicine, 2023 Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) represent the first agents in a rapidly evolving, highly promising landscape of
Ania M Jastreboff, R. Kushner
exaly +2 more sources
Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. [PDF]
PLoS ONE, 2010 GLP-1 has a variety of anti-diabetic effects. However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2168 h. Intraperitoneal glucose tolerance test (IPGTT) in mice showed that GLP-1/hIgG2 significantly decreased ...
Qinghua Wang +6 more
doaj +4 more sources
Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes [PDF]
Electronic Physician, 2013 Background: The aim of this study was to examine the effect of purslane seeds in glucagon-like peptide-1 concentration and glucagon-like peptide-1 receptor in women with diabetes. Methods: This was a quasi-experimental study.
Sara Heidarzadeh +3 more
doaj +4 more sources
An Update on GLP‐1 Receptor Agonists [PDF]
Journal of DiabetesZachary Bloomgarden
doaj +2 more sources